Evidence map›Paper›PMID 42792112›Full record

ArticleAntioxidants (Basel, Switzerland)2026

Dual Targeting of Galanin Receptor 3 Signaling and Redox Homeostasis Enhances Photoreceptor Survival in Retinas of

Maria Azam, Mingda Liu, Beata Jastrzebska

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maria AzamDepartment of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
Mingda LiuDepartment of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
Beata JastrzebskaDepartment of Pharmacology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.ORCID 0000-0001-5209-8685

Funding

TISSUE CULTURE AND HYBRIDOMA MODULEP30EY011373 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI Irina A Pikuleva · 1997 to 2026
$17.7M
Novel neuroprotective activities of flavonoids against retinal degenerative diseasesR01EY032874 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI JASTRZEBSKA, BEATA · 2022 to 2025
$1.9M
Cole Eye Institute Vision Science Training ProgramT32EY024236 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI ANAND-APTE, BELA · 2015 to 2025
$1.0M
Predoctoral Training in Molecular PharmacologyT32GM158814 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Jason Mears, Marvin Thomas Nieman · 2025 to 2026
$858k
NEI NIH HHS P30 EY011373NEI NIH HHS R01 EY032874NEI NIH HHS T32 EY024236NIGMS NIH HHS T32 GM158814NIH HHS 1R01EY032874-04NIH HHS 1T32GM158814-01NIH HHS 5T32EY024236-09
6 · The paper itself

Abstract

Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal degenerative disorders characterized by progressive photoreceptor loss and vision impairment, for which broadly applicable mutation-independent therapies remain limited. To examine the therapeutic potential of combined galanin receptor 3 (GALR3) inhibition and antioxidant therapy in a mutation-independent context, we utilized the

Indexed as

galanin receptorsneuroinflammationoxidative stressphotoreceptorquercetinretinal degenerationretinitis pigmentosa

Identifiers

PMID42792112
PMCPMC13603368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.